Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

ACCC releases preliminary results from survey on stage III and IV lung cancer care

The Association of Community Cancer Centers today released preliminary results and an initial set of quality care recommendations from Fostering Excellence in Care and Outcomes in Patients with Stage III and IV NSCLC, an initiative to improve care delivery and outcomes for advanced non-small cell lung cancer (NSCLC) patients.

23 Jun 2020

Study highlights role of EGFR mutations in predicting recurrence in lung cancer

Volume 11, Issue 22 of @Oncotarget reported that while lobectomy can improve mortality in this group, about 30 55% of patients will experience disease recurrence.

10 Jun 2020

Oncotarget: mi R-151a overexpression enhances tumor-associated angiogenesis

Volume 11, Issue 23 of @Oncotarget reported that the authors have previously established that mi R-151a functions as an onco-mi R in non-small cell lung cancer cells by inducing partial EMT and enhancing tumor growth.

10 Jun 2020

Study reveals outcomes of radiosurgery for patients with brain metastases from small cell lung cancer

The international First-line Radiosurgery for Small-Cell Lung Cancer analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery, without prior treatment with whole-brain radiation or prophylactic cranial irradiation.

5 Jun 2020

New analysis supports first-line stereotactic radiosurgery for small cell lung cancer

The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).

5 Jun 2020

New immunotherapy for metastatic non-small cell lung cancer shows promise in clinical trial

A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System.

30 May 2020

Newer treatment approaches may reduce risk of therapy-related hematologic cancers

While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.

29 May 2020

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology Annual Meeting ASCO20 Virtual Meeting (Abstract 9556 - Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy shows immense benefit for patients with early stage NSCLC

According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.

29 May 2020

New AI tool could predict risk of lung cancer recurrence

Computer scientists working with pathologists have trained an artificial intelligence tool to determine which patients with lung cancer have a higher risk of their disease coming back after treatment, as part of Cancer Research UK’s landmark TRACERx study.

26 May 2020

Molecular testing rates in most countries less than 50%, IASLC survey finds

Access to targeted therapies for lung cancer depends on accurate identification of patients' biomarkers through molecular testing, but survey results published today in the Journal of Thoracic Oncology suggest that many international clinicians are unaware of evidence-based guidelines that support the use of molecular testing.

20 May 2020

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Takeda Pharmaceutical Company Limited today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two upcoming virtual scientific congresses: the 56th Annual Meeting of the American Society of Clinical Oncology, May 29-31 and the 25th Virtual Congress of the European Hematology Association, June 11-14.

18 May 2020

Experts publish a review of lung cancer treatments for patients with COVID-19

Lung cancer patients are at heightened risk for COVID-19 and the reported high mortality rate among lung cancer patients with COVID-19 has given pause to oncologists who are faced with patients with not one, but two severe, life-threatening diseases.

15 May 2020

Patients with aggressive form of skin cancer can benefit from new type of immunotherapy

In what is believed to be a first-of-its-kind study to evaluate the safety of a type of immunotherapy before surgery in patients with an aggressive form of skin cancer, researchers report that the treatment eliminated pathologic evidence of cancer in nearly half of the study participants undergoing surgery.

27 Apr 2020

Combinations of PAC and WFA are highly synergistic against proliferation of non-small cell lung cancer

Oncotarget Volume 11 Issue 16 showed that the sensitivity of H1299 and A549 cells to concomitant treatment with PAC and WFA was greater than that of either PAC or WFA alone.

23 Apr 2020

Series of rare side effects underscores the need to track targeted anti-cancer drugs

Tejas Patil, MD, is a medical oncologist. Lisa Ferrigno, MD, MPH, FACS, is a trauma surgeon. Working with lung cancer patients at University of Colorado Cancer Center, they both, independently, noticed something strange:

23 Apr 2020

Researchers uncover how cancer cells don their invisibility cloaks

Immunotherapy drugs that target a protein called programmed death ligand 1 (PD-L1) on the surface of cancer cells have quickly become a mainstay to treat many forms of cancer, often with dramatic results. But exactly how cancer cells turn on this protein was not completely understood.

22 Apr 2020

Targeting specific histone deacetylase may be novel therapeutic strategy for NSCLC

The survival rates for patients with non-small cell lung cancer have improved greatly over the past decade thanks to several new targeted treatment options for patients.

26 Mar 2020

Non Small Cell Lung Cancer News and Research

ACCC releases preliminary results from survey on stage III and IV lung cancer care

Study highlights role of EGFR mutations in predicting recurrence in lung cancer

Oncotarget: mi R-151a overexpression enhances tumor-associated angiogenesis

Study reveals outcomes of radiosurgery for patients with brain metastases from small cell lung cancer

New analysis supports first-line stereotactic radiosurgery for small cell lung cancer

New immunotherapy for metastatic non-small cell lung cancer shows promise in clinical trial

Newer treatment approaches may reduce risk of therapy-related hematologic cancers

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

Targeted therapy shows immense benefit for patients with early stage NSCLC

New AI tool could predict risk of lung cancer recurrence

Molecular testing rates in most countries less than 50%, IASLC survey finds

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Experts publish a review of lung cancer treatments for patients with COVID-19

Patients with aggressive form of skin cancer can benefit from new type of immunotherapy

Combinations of PAC and WFA are highly synergistic against proliferation of non-small cell lung cancer

Series of rare side effects underscores the need to track targeted anti-cancer drugs

Researchers uncover how cancer cells don their invisibility cloaks

Targeting specific histone deacetylase may be novel therapeutic strategy for NSCLC

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News